<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Clin Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Int J Clin Pharm</journal-id><journal-title-group><journal-title>International Journal of Clinical Pharmacy</journal-title></journal-title-group><issn pub-type="ppub">2210-7703</issn><issn pub-type="epub">2210-7711</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5694509</article-id><article-id pub-id-type="pmid">29139019</article-id><article-id pub-id-type="publisher-id">551</article-id><article-id pub-id-type="doi">10.1007/s11096-017-0551-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Pharmacists&#x02019; confidence when providing pharmaceutical care on anticoagulants, a multinational survey</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Papastergiou</surname><given-names>John</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kheir</surname><given-names>Nadir</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ladova</surname><given-names>Katerina</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rydant</surname><given-names>Silas</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>De Rango</surname><given-names>Fabio</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Antoniou</surname><given-names>Sotiris</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Viola</surname><given-names>Reka</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Murillo</surname><given-names>Maria Dolores</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Steurbaut</surname><given-names>Stephane</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0562-2514</contrib-id><name><surname>da Costa</surname><given-names>Filipa Alves</given-names></name><address><email>filipa.alvesdacosta@ipact.org</email></address><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution>Leslie Dan Faculty of Pharmacy, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, ON M4J 1L2 Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8644 1405</institution-id><institution-id institution-id-type="GRID">grid.46078.3d</institution-id><institution>School of Pharmacy, </institution><institution>University of Waterloo, </institution></institution-wrap>755 Danforth Avenue, Toronto, ON M4J 1L2 Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0634 1084</institution-id><institution-id institution-id-type="GRID">grid.412603.2</institution-id><institution>College of Pharmacy, </institution><institution>Qatar University, </institution></institution-wrap>PO Box 2713, Doha, Qatar </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 116X</institution-id><institution-id institution-id-type="GRID">grid.4491.8</institution-id><institution>Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, </institution><institution>Charles University, </institution></institution-wrap>Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic </aff><aff id="Aff5"><label>5</label>Pharmaceutical Care Division (Meduca), Royal Pharmacists Association of Antwerp (KAVA), Lange Leemstraat 187, 2018 Antwerpen, Belgium </aff><aff id="Aff6"><label>6</label>Shoppers Drug Mart 1271, 2501 Third Line, Oakville, ON L6M 5A9 Canada </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0372 5777</institution-id><institution-id institution-id-type="GRID">grid.139534.9</institution-id><institution>Barts Health Centre; Barts Health NHS Trust, </institution></institution-wrap>London, UK </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution>UCL Partners, </institution></institution-wrap>London, UK </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1016 9625</institution-id><institution-id institution-id-type="GRID">grid.9008.1</institution-id><institution>Department of Clinical Pharmacy, Faculty of Pharmacy, </institution><institution>University of Szeged, </institution></institution-wrap>Szikrautca 8, Szeged, 6724 Hungary </aff><aff id="Aff10"><label>10</label>Farmacia Fern&#x000e1;ndez Vega C.B., C/Par n&#x000ba; 26 Urbanizaci&#x000f3;n Club de Golf. Alcal&#x000e1; de Guadaira, Sevilla, 41500 Spain </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2290 8069</institution-id><institution-id institution-id-type="GRID">grid.8767.e</institution-id><institution>Research Group Clinical Pharmacology&#x00026; Clinical Pharmacy (KFAR), Faculty of Medicine and Pharmacy, </institution><institution>Vrije Universiteit Brussel, </institution></institution-wrap>Laarbeeklaan 101, 1090 Brussels, Belgium </aff><aff id="Aff12"><label>12</label>Centro de Investiga&#x000e7;&#x000e3;o Interdisciplinar Egas Moniz (CiiEM), Campus Universit&#x000e1;rio, Quinta da Granja, Monte da Caparica, 2829-551 Caparica, Portugal </aff><aff id="Aff13"><label>13</label>Portuguese Pharmaceutical Society (PPS), Rua da Sociedade Farmac&#x000ea;utica, 18, 1169-075 Lisboa, Portugal </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>39</volume><issue>6</issue><fpage>1282</fpage><lpage>1290</lpage><history><date date-type="received"><day>17</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">
<italic>Background</italic> Guidelines on the management of orally anticoagulated patients are continuously evolving, leading to an increased need for pharmacists to be fully integrated in care provision. <italic>Objective</italic> To identify self-reported gaps in confidence among practicing pharmacists in the area of anticoagulation. <italic>Setting</italic> Pharmacists in different work settings in different countries. <italic>Method</italic> Cross-sectional international survey from October 2015 till November 2016 among pharmacists working in different settings to assess their level of confidence when delivering anticoagulants as well as to identify possible educational needs regarding this medication class. Validation of the survey was ensured. <italic>Results</italic> Responses from 4212 pharmacists originating from 18 countries were obtained. Pharmacists&#x02019; level of confidence was significantly higher (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) when advising patients on vitamin K antagonists (VKAs) versus non-vitamin K antagonists (NOACs). In general, hospital pharmacists displayed higher confidence levels compared to community pharmacists when advising patients on anticoagulation (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Two distinct patterns of confidence levels emerged relating to basic and advanced pharmaceutical care. Confidence levels when providing advanced pharmaceutical care were significantly higher for Oceania and lower for South America (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.005). <italic>Conclusions</italic> Pharmacists felt more confident in supporting patients receiving VKAs compared to the more recently introduced NOACs. With the increasing use of NOACs and the risks pertaining to anticoagulation therapy, it is essential to invest in education for pharmacists to address their knowledge gaps enabling them to confidently support patients receiving oral anticoagulants.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s11096-017-0551-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Anticoagulants</kwd><kwd>Education, pharmacy</kwd><kwd>iPACT</kwd><kwd>Knowledge</kwd><kwd>Needs assessment</kwd><kwd>Pharmacists</kwd></kwd-group><funding-group><award-group><funding-source><institution>DRM Foundation</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing AG, part of Springer Nature 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Impact of findings on practice</title><p>
<list list-type="bullet"><list-item><p id="Par2">Education of pharmacists in anticoagulation is essential for improved pharmaceutical patient care</p></list-item><list-item><p id="Par4">Pharmacists perceive a greater need for education on more recently marketed anticoagulants</p></list-item><list-item><p id="Par6">Pharmacists identify e-learning as the preferred method of educational content delivery</p></list-item></list>
</p></sec><sec id="Sec2" sec-type="introduction"><title>Introduction</title><p id="Par8">Venous thromboembolism (VTE) and atrial fibrillation (AF) are two health conditions that require complex anticoagulation therapy for management and for prevention of life-threatening thromboembolic events. It is estimated that 10 million new cases of VTE are diagnosed annually resulting in over 544,000 deaths per year in Europe and 300,000 deaths per year in the US [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. As 60% of VTE cases occur after hospitalization, it is a leading preventable cause of hospital-related death [<xref ref-type="bibr" rid="CR1">1</xref>]. Globally, there are 33.5 million patients afflicted with AF [<xref ref-type="bibr" rid="CR4">4</xref>]. It has been reported that as many as 10&#x02013;27% of patients with AF remain undiagnosed [<xref ref-type="bibr" rid="CR5">5</xref>]. AF can lead to ischemic stroke, and patients with AF are at a five-fold increased risk of stroke compared to the general population [<xref ref-type="bibr" rid="CR6">6</xref>]. Depending on an individual&#x02019;s CHADS<sub>2</sub> score, the estimated risk of stroke ranges from 1.9 to 18.2% if a patient with AF does not receive anticoagulation [<xref ref-type="bibr" rid="CR7">7</xref>]. In the US, 1 in 5 of the 700,000 strokes which occur annually are attributed to AF, and this proportion increases to 1 in 3 in those aged over 80&#x000a0;years [<xref ref-type="bibr" rid="CR8">8</xref>]. Ultimately, patients with AF have a two-fold increased risk of mortality compared to the general population [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par9">Oral anticoagulants are the standard modality for the treatment of these conditions. Compared to placebo, there is an 83% decrease in the recurrence of VTE with warfarin or non-vitamin K oral anticoagulant (NOAC) therapy [<xref ref-type="bibr" rid="CR9">9</xref>]. Likewise, warfarin reduces the risk of ischemic stroke by 60% in patients with AF [<xref ref-type="bibr" rid="CR10">10</xref>]. Comparatively, the NOACs have been shown to be either non-inferior or superior when compared to warfarin for stroke prophylaxis in AF [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par10">Although warfarin was the most widely used OAC globally since its approval in 1954, the use of NOACs has steadily increased since the availability of dabigatran in 2008. In 2014, NOACs accounted for 15.5% of the global anticoagulant market whereas warfarin use had declined to 72% [<xref ref-type="bibr" rid="CR15">15</xref>]. Furthermore, studies have estimated a three-fold increase in NOAC use between 2013 and 2014 in the United States (US) for AF [<xref ref-type="bibr" rid="CR16">16</xref>]. This increase in use is likely attributed to the demonstrated safety, efficacy, and convenience of the newer agents, and the lack of international normalized ratio (INR) monitoring or individualized dose adjustments [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Nonetheless, patients are less likely to receive frequent follow-up as there is no standardized routine monitoring performed to assess the anticoagulation effects of the NOACs [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. While INR may serve as an indicator of patient adherence with warfarin, patient self-reported intake is the predominant adherence assessment used with NOACs [<xref ref-type="bibr" rid="CR19">19</xref>]. A recent dabigatran analysis revealed that a 10% decrease in adherence resulted in a 13% increased stroke risk secondary to AF [<xref ref-type="bibr" rid="CR20">20</xref>]. As such, patient monitoring, education, and medication adherence are of critical importance with these novel agents, given the difference in methods for assessing it as well as the consequences of non-adherence due to the NOACs&#x02019; shorter half-lives.</p><p id="Par11">The scope of pharmacy practice continues to evolve globally, and pharmacists are uniquely positioned to play a broader role in anticoagulation medication management. Several studies have documented the positive impact from pharmacists in monitoring and managing warfarin in the community setting. These benefits include an increased percentage of INR measurements within therapeutic range, increased patient understanding of their medication, and reduced-rates of anticoagulation-related emergency room visits and hospitalizations [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Given that self-reported adherence rates with NOACs are as low as 57% [<xref ref-type="bibr" rid="CR24">24</xref>], pharmacists may be able to have a similar impact on patients receiving NOAC therapy.</p><p id="Par12">The International Pharmacists for Anticoagulation Care Taskforce (iPACT) is an expert group committed to further enhance the key role pharmacists play in anticoagulation management. Whilst pharmacists are well suited to monitor patients receiving oral anticoagulation, to our knowledge, an assessment of their knowledge in providing consultations has not been formally undertaken. Historically, needs assessment surveys have been successfully used to identify the self-perceived confidence of pharmacists in emerging therapeutic fields and to identify professional needs prior to developing continuing professional education and development programs [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p></sec><sec id="Sec3"><title>Aim of the study</title><p id="Par13">The main study purpose was to identify self-reported gaps in knowledge and confidence among pharmacists in the area of anticoagulation and to explore preferred educational methods to close these gaps. An additional objective was to identify any difference in confidence levels between countries.</p></sec><sec id="Sec4"><title>Ethics approval</title><p id="Par14">This study was centrally approved by the Comiss&#x000e3;o de &#x000c9;tica Egas Moniz in Portugal (Process no. 489). In all countries, pharmacists were free to decline participation. The principles of ethical research practices were followed, such as confidentiality, freedom to participate or withdraw at any stage, and anonymity.</p></sec><sec id="Sec5" sec-type="materials|methods"><title>Methods</title><sec id="Sec6"><title>Design and procedure</title><p id="Par15">This study was a cross-sectional international survey (available as electronic supplementary material) among pharmacists working in different settings to assess their level of confidence when delivering anticoagulants as well as to identify possible educational needs regarding this medication class. The questionnaire was originally developed and validated in English, following literature review, consultation with external experts and input from iPACT members experienced in survey development. The Decipher software (version M35; Quest Mindshare, Toronto, Canada) was used for developing the web-based survey; and data extraction was programmed on WinCross 14.0. The questionnaire consisted of three parts. The first part (including 6 items) collected participants&#x02019; demographic information such as years of work experience, level of education and area of practice. The second part (including 13 items) explored pharmacists&#x02019; confidence levels when advising patients on various aspects of anticoagulation medication, and was ranked on a 4 point Likert scale, ranging from &#x0201c;very confident&#x0201d; to &#x0201c;not confident at all&#x0201d;. The second part of the survey also asked about information sources sought to support patient counselling. The last part (including 6 items) gauged the perceived educational needs of the pharmacists and asked about the preferred format and tools to deliver this education. The survey was translated into 19 different languages and distributed in 22 countries after being piloted. Piloting was performed by administration to 10 pharmacists per country and to assess the burden, applicability, and acceptability among respondents. Subsequently, the first countries where data collection was undertaken (France and Canada), were used to validate the survey, which comprised testing psychometric properties in a sample of respondents. The process was then replicated in all participating countries. The survey was distributed electronically using each iPACT country coordinator&#x02019;s network. The most common method involved using the national and/or regional professional pharmacy associations for dissemination. Since countries joined the project at different times, the survey was allowed to run from October 2015 until November 2016. In all countries, the national coordinator was free to decide on the length of data collection, which depended mainly on the partner associations involved in disseminating the survey and the time to reach the minimum number of 50 respondents per country. The minimum period to achieve this was 1&#x000a0;month and the maximum 6&#x000a0;months. In all countries, mail alerts were used as a reminder technique to increase the response rate.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par16">The survey&#x02019;s construct validity was examined using factor analysis. Internal consistency and homogeneity were examined by calculating Cronbach&#x02019;s alpha. Categorical data was summarized as frequencies and percentages. Comparison between groups was performed using the Chi square test while comparison of continuous variables was performed using independent sample <italic>t</italic> test or ANOVA. Depending on the number of groups under comparison, Bonferroni post hoc tests were utilized as required. Linear regression was performed to assess the effects of potential predictors on pharmacists&#x02019; confidence levels (dependent variable) when advising patients on anticoagulation medication. Predictors tested (independent variables) included age, years of experience, educational level, area of practice and country of origin. Statistical analyses were executed with a 0.05 significance level using IBM SPSS Statistics version 23 (IBM Corp., Armonk, NY, USA).</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Characterisation of respondents</title><p id="Par17">A total of 4255 responses from 21 countries were collected. Countries with no responses (Peru) or with a low response rate (USA, Slovenia and Chile) were subsequently excluded. As such, 18 countries with a total of 4212 responses were retained in the final analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The final list of the countries included were representative of Europe (66.7%), North and South America (5.6 and 11.1%, respectively), Oceania (11.1%), and the Gulf Council Countries (5.6%).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Distribution of respondents to the iPACT survey by country of origin</p></caption><graphic xlink:href="11096_2017_551_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par18">The majority of respondents were female pharmacists (n&#x000a0;=&#x000a0;3045; 72.3%), mostly middle aged between 30 and 50&#x000a0;years. Experience in pharmacy varied widely, unlike formal education where only a minority held a PhD. 67.7% (n&#x000a0;=&#x000a0;2852) of respondents worked in a community pharmacy, while 27.5% (n&#x000a0;=&#x000a0;1157) worked in a hospital. Other areas of employment, including academia, the pharmaceutical industry, and independent consultancy firms, represented a much lower proportion of the sample population.</p></sec><sec id="Sec10"><title>Confidence levels of pharmacists</title><p id="Par19">Pharmacists&#x02019; level of confidence was significantly higher when advising patients on vitamin K antagonists (VKAs) versus NOACs (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Distribution of pharmacists&#x02019; confidence by pharmacotherapeutic group</p></caption><graphic xlink:href="11096_2017_551_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par20">Distinct patterns in confidence level were observed depending on the surveyed items (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). There were no differences in the confidence levels that could be explained by the age of pharmacists, their experience of pharmacy practice or additional formal education (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05) (results not shown). In general, hospital pharmacists displayed higher confidence levels compared to community pharmacists when advising patients on anticoagulation (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). However, country specific differences in confidence levels associated with area of practice were observed; for instance in Belgium, community pharmacists performed similarly to hospital pharmacists.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Distribution of pharmacists&#x02019; confidence by counselling item</p></caption><graphic xlink:href="11096_2017_551_Fig3_HTML" id="MO3"/></fig>
</p><p id="Par21">The underlying themes included in the questionnaire could be clustered into two main categories. The first group focused on delivering drug and disease-related information such as drug indications or expected benefits of treatment. In some countries, this practice is a compulsory part of basic pharmaceutical care. The second category included delivering more advanced pharmaceutical care and requiring the pharmacist to manage more complex issues such as the identification and treatment of bleeds. This categorization was confirmed by the rotated factor plotting, clearly visualizing that the individual items load into the respective components described (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Component plot in rotated space</p></caption><graphic xlink:href="11096_2017_551_Fig4_HTML" id="MO4"/></fig>
</p><p id="Par22">The two components shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, basic pharmaceutical care and advanced pharmaceutical care, displayed high internal consistency in the overall sample (&#x003b1;&#x000a0;=&#x000a0;0.851 and &#x003b1;&#x000a0;=&#x000a0;0.877, respectively), with insignificant variations at the country level (ranging from 0.757 to 0.878 for component 1 and from 0.772 to 0.924 for component 2).</p><p id="Par23">Analysis of confidence levels by continent of origin identified differences between the groups for the two components (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Post-hoc analysis highlighted that with regard to confidence levels when providing patients with basic pharmaceutical care (component 1), only South American countries performed significantly lower than all others (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). On the other hand, two extremes in confidence levels were detected when providing patients with advanced pharmaceutical care (component 2). South American countries performed significantly lower and Oceania performed significantly better (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.005) in this regard compared to all others (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Comparison of confidence levels by continent of practice of pharmacists</p></caption><graphic xlink:href="11096_2017_551_Fig5_HTML" id="MO5"/></fig>
</p><p id="Par24">Linear regression was used to analyse predictors of pharmacists&#x02019; confidence levels. Two independent models were considered, where component 1 and component 2 were the dependent variables. Whilst both models were found to predict very little of the variability (R<sup>2</sup>&#x000a0;=&#x000a0;0.196 and R<sup>2</sup>&#x000a0;=&#x000a0;0.233, respectively), the same variables were found to influence confidence levels, suggesting that gender, length of experience, post-graduate education, and area of practice may indeed partly explain self-confidence. On the other hand, continent of origin was identified as an additional predictor but only for component 2 (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Results from linear regression using components 1 and 2 on &#x0201c;confidence when advising patients on anticoagulation care&#x0201d; as the dependent variable (n&#x000a0;=&#x000a0;4212)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Adjusted &#x003b2;</th><th align="left">95% CI</th><th align="left">
<italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="4">
<italic>Factor 1: Basic pharmaceutical care</italic>
</td></tr><tr><td align="left">Constant</td><td align="left"/><td char="." align="char">18.318;19.991</td><td char="." align="char">&#x0003c;&#x000a0;0.001</td></tr><tr><td align="left">Gender</td><td char="." align="char">&#x02212;&#x000a0;0.159</td><td char="." align="char">&#x02212;&#x000a0;1.399; &#x02212;&#x000a0;0.953</td><td char="." align="char">&#x0003c;&#x000a0;0.001</td></tr><tr><td align="left">Experience of pharmacy</td><td char="." align="char">0.096</td><td char="." align="char">0.138; 0.265</td><td char="." align="char">&#x0003c;&#x000a0;0.001</td></tr><tr><td align="left">Additional education</td><td char="." align="char">0.041</td><td char="." align="char">0.023; 0.162</td><td char="." align="char">0.009</td></tr><tr><td align="left">Area of practice</td><td char="." align="char">&#x02212;&#x000a0;0.035</td><td char="." align="char">&#x02212;&#x000a0;0.357; &#x02212;&#x000a0;0.024</td><td char="." align="char">0.025</td></tr><tr><td align="left" colspan="4">
<italic>Factor 2: Advanced pharmaceutical care</italic>
</td></tr><tr><td align="left">Constant</td><td align="left"/><td char="." align="char">13.744; 15.618</td><td char="." align="char">&#x0003c;&#x000a0;0.001</td></tr><tr><td align="left">Gender</td><td char="." align="char">&#x02212;&#x000a0;0.157</td><td char="." align="char">&#x02212;&#x000a0;1.560; &#x02212;&#x000a0;1.060</td><td char="." align="char">&#x0003c;&#x000a0;0.001</td></tr><tr><td align="left">Experience of pharmacy</td><td char="." align="char">0.084</td><td char="." align="char">0.128; 0.271</td><td char="." align="char">&#x0003c;&#x000a0;0.001</td></tr><tr><td align="left">Additional education</td><td char="." align="char">0.083</td><td char="." align="char">0.271; 0.294</td><td char="." align="char">&#x0003c;&#x000a0;0.001</td></tr><tr><td align="left">Area of practice</td><td char="." align="char">&#x02212;&#x000a0;0.074</td><td char="." align="char">&#x02212;&#x000a0;0.643; &#x02212;&#x000a0;0.270</td><td char="." align="char">&#x0003c;&#x000a0;0.001</td></tr><tr><td align="left">Continent</td><td char="." align="char">0.090</td><td char="." align="char">0.756; 1.511</td><td char="." align="char">&#x0003c;&#x000a0;0.001</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec11"><title>Preferred sources of information for pharmacists and educational needs</title><p id="Par25">When dispensing anticoagulants, pharmacists chose specialized pharmacy software as their preferred source of information (n&#x000a0;=&#x000a0;2350; 55.8%), followed by the internet (n&#x000a0;=&#x000a0;2186; 51.9%). Less than half of the respondents used reference books (n&#x000a0;=&#x000a0;1790; 42.5%) or published journal articles (n&#x000a0;=&#x000a0;1255; 29.8%).</p><p id="Par26">The majority of respondents (n&#x000a0;=&#x000a0;3871; 91.9%) reported that they would like to receive additional education to improve their confidence level. The preferred areas for further education followed an inverse trend compared to the expressed confidence levels. The most desired item in this regard was interactions (n&#x000a0;=&#x000a0;2956; 70.2%), followed by management of bleeding (n&#x000a0;=&#x000a0;2871; 68.2%), and management of switching (n&#x000a0;=&#x000a0;2780; 66.0%). Management of bleeding was among the top areas receiving educational requests, while learning about the coagulation pathway was the least requested topic (n&#x000a0;=&#x000a0;1322; 31.4%).</p><p id="Par27">The most popular formats of education were personalized e-learning (n&#x000a0;=&#x000a0;2490; 59.1%), interactive websites (n&#x000a0;=&#x000a0;1760; 41.8%) and symposia (n&#x000a0;=&#x000a0;1757; 41.7%). The least preferred formats identified were education from peers (n&#x000a0;=&#x000a0;493; 11.7%), webinars (n&#x000a0;=&#x000a0;970; 23.0%) and workshops (n&#x000a0;=&#x000a0;1473; 35.0%). While these results reflect the overall trend, there were country-specific behaviours, where for example education from peers was more popular among Dutch pharmacists and webinars amongst Croatians pharmacists.</p><p id="Par28">In addition to education, pharmacists expressed the need to have a list of frequently asked questions to support them while counselling patients (n&#x000a0;=&#x000a0;4043; 96.0%). A quick reference guide was proposed as a solution, either embedded in the pharmacy software (2754; 65.4%), as a link to a website (n&#x000a0;=&#x000a0;2200; 52.2%) or as a specific app (n&#x000a0;=&#x000a0;1797; 42.7%). Non-technological solutions were less favoured, e.g. the availability of a pocket guide.</p></sec></sec><sec id="Sec12" sec-type="discussion"><title>Discussion</title><p id="Par29">To the best of our knowledge, this is the first global study that reports data from pharmacists on perceived gaps in confidence and training needs in the area of anticoagulation therapy. The diverse, transcontinental sample provides a valuable snapshot of the status of pharmacists with respect to their preparedness to provide counselling and education related to these potentially risky treatment modalities.</p><p id="Par30">Non-vitamin K oral anticoagulants have been introduced into the market relatively recently as an alternative to warfarin, and our results showed a higher level of confidence among pharmacists advising patients on VKAs than on NOACs. This reflects the long experience with VKAs, which have been the mainstay of treatment globally for a much longer period. However, the complexity of therapies associated with VTE and AF requires an advanced level of practice, regardless of the anticoagulant used. Warfarin is consistently reported within the top 3 medications associated with an adverse reaction leading to a hospital admission [<xref ref-type="bibr" rid="CR27">27</xref>]. Guidelines recommend that healthcare providers who are managing oral anticoagulation therapy should incorporate, in a coordinated manner, patient education, patient tracking and follow-up and good patient communication regarding the results and dosing decisions [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. For patients receiving VKA anticoagulation therapy, careful INR testing is key to ensuring treatment success, preventing thromboembolic events, and managing bleeding risks. Such an advanced level of practice is typically seen in countries known to have well-developed pharmacy practice standards and regulations that support those standards. The results with respect to pharmacist confidence levels with anticoagulation therapies mirrored this relationship. Respondents from Ireland, the UK, the Netherlands, Australia, Canada, and New Zealand expressed higher levels of confidence in dealing with VKAs and NOACs than respondents from the other countries. Respondents from South America were persistently less confident. Experience with NOACs and their use in routine practice differs between countries; and this may be influenced by health economics, pricing, and coverage by different health systems [<xref ref-type="bibr" rid="CR28">28</xref>]. Higher gross domestic product (GDP) countries, for example, do tend to have advanced pharmacy practice in contrast with lower GDP nations [<xref ref-type="bibr" rid="CR30">30</xref>]. This most likely explains the reason for the higher confidence illustrated in our results. Site of practice also has an association with the level of perceived confidence in dealing with anticoagulation management. In general, hospital pharmacists expressed higher confidence than pharmacists in other localities. This could be attributed to several factors. For example, the job demands in a hospital setting, the interprofessional environment in hospital practice, and the opportunity for professional development in many hospitals could explain this result. In contrast, community pharmacy in &#x02018;developing&#x02019; countries is still dominated by the more traditional dispensing practice.</p><p id="Par31">Over 90% of the participants expressed desire for some sort of continuing education on different aspects of anticoagulation management. Assessing training needs was an important objective in this study. While this was an opportunity for reflection from the perspective of the pharmacist, it helps in the development of relevant educational programs tailored to the perceived needs. The results of this study have also provided us with an insight on what information is desired, and in what format this information should be provided. Methods for learning spanned a wide range of options, with e-learning and interactive websites being the most popular. All this information should prove invaluable in developing continuous education materials to close the knowledge gaps identified by this study. Other studies using similar (web-based survey) or comparable techniques (interview, questionnaire) have also identified pharmacists&#x02019; knowledge gaps and education needs in domains such as transplantation, travel health, weight loss and oral health [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par32">This study has some limitations, including the inability to include a larger sample in some relevant countries represented by iPACT members, like the USA or Chile, leading us to exclude them in the final analysis. Nonetheless, data collection is ongoing in these countries and may be used in the future to shape pharmacists&#x02019; education. The inability to represent African countries and include only Gulf Council countries (Kuwait, Qatar, Saudi Arabia and the United Arab Emirates) as representatives of the Asian continent limits comparisons. However, the similarities in pharmacy practice, demographics and education of Gulf Council countries allowed for a valid grouping of these individual countries [<xref ref-type="bibr" rid="CR35">35</xref>]. Within participating countries, selection bias may have occurred by using an internet survey. However, in Portugal data was compared against national data of pharmacists&#x02019; demographics, and this showed only minor discrepancies [<xref ref-type="bibr" rid="CR36">36</xref>]. The simplified translation process utilized may have led to some inadequate terminology use, but the high consistency evidenced led us to discard this possibility.</p></sec><sec id="Sec13" sec-type="conclusion"><title>Conclusion</title><p id="Par33">Pharmacists reported higher confidence in supporting patients receiving VKAs compared to the more recently introduced NOACs. Consistently, pharmacists had greatest confidence in explaining the indication and the benefits of anticoagulation and lowest confidence in managing bleeding and switching amongst oral anticoagulants. With the increasing use of NOACs and the known risks pertaining to anticoagulation therapy, it is essential to invest in education for pharmacists to address their knowledge gaps enabling them to confidently support patients receiving oral anticoagulants.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec14"><p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11096_2017_551_MOESM1_ESM.doc"><caption><p>Supplementary material 1 (DOC 64&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1007/s11096-017-0551-2) contains supplementary material, which is available to authorized users.</p></fn><fn><p>A correction to this article is available online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11096-017-0586-4">https://doi.org/10.1007/s11096-017-0586-4</ext-link>.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to acknowledge all the organisations that have facilitated this survey and helped in its dissemination: Portuguese Pharmaceutical Society, Royal Pharmacist Association of Antwerpen (KAVA), Association of Flemish Hospital Pharmacists (VZA), Belgian Institute for Continuing Education for Pharmacists (IPSA), Soci&#x000e9;t&#x000e9; Fran&#x000e7;aise de Pharmacie Clinique and Syndicat National des Pharmaciens des &#x000c9;tablissements Publics de Sant&#x000e9;, Pharmaceutical Society of New Zealand, Pharmaceutical Society of Australia, Hungarian Chamber of Pharmacists, Sociedad Espa&#x000f1;ola de Farmacia Familiar y Comunitaria, Brazilian Society of Hospital Pharmacy and Health Services (SBRAFH), Croatian Chamber of pharmacists and the Croatian Pharmaceutical Society, Czech Chamber of Pharmacists, Canadian Pharmacist Association, The Royal Pharmaceutical Society of Great Britain. They are also grateful to the individuals that made data collection possible: Cassyano Correr (Brazil), Elena Mar&#x000ed;a Veja (Chile), Sonia Uema (Argentina) and Anna Olearova (Slovakia). In addition, they acknowledge Mr. Ales Antonin Kubena for the statistical support as well as all project collaborators and members of iPACT.</p><sec id="FPar2"><title>Funding</title><p id="Par35">The project was funded by the Davie-Ratnoff-Macfarlane (DRM) foundation.</p></sec></ack><notes notes-type="COI-statement"><sec id="FPar1"><title>Conflicts of interest</title><p id="Par34">The DRM foundation received educational and research support grants from Bayer.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>AK</given-names></name><name><surname>Larizgoitia</surname><given-names>I</given-names></name><name><surname>Audera-Lopez</surname><given-names>C</given-names></name><name><surname>Prasopa-Plaisier</surname><given-names>N</given-names></name><name><surname>Waters</surname><given-names>H</given-names></name><name><surname>Bates</surname><given-names>DW</given-names></name></person-group><article-title>The global burden of unsafe medical care: analytic modeling of observational studies</article-title><source>BMJ Qual Saf.</source><year>2013</year><volume>22</volume><fpage>809</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1136/bmjqs-2012-001748</pub-id><?supplied-pmid 24048616?><pub-id pub-id-type="pmid">24048616</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">US Department of Health and Human Services. Surgeon General&#x02019;s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. 2008. <ext-link ext-link-type="uri" xlink:href="http://www.surgeongeneral.gov/topics/deepvein">http://www.surgeongeneral.gov/topics/deepvein</ext-link>.</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Heit JA. Poster 68 presented at: American society of hematology. In: 47th Annual Meeting, Atlanta, GA, December 10&#x02013;13, 2005.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chug</surname><given-names>SS</given-names></name><name><surname>Havmoeller</surname><given-names>R</given-names></name><name><surname>Narayanan</surname><given-names>K</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Rienstra</surname><given-names>M</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study</article-title><source>Circulation</source><year>2014</year><volume>129</volume><fpage>837</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.005119</pub-id><pub-id pub-id-type="pmid">24345399</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowres</surname><given-names>N</given-names></name><name><surname>Neubeck</surname><given-names>L</given-names></name><name><surname>Redfern</surname><given-names>J</given-names></name><name><surname>Freedman</surname><given-names>SB</given-names></name></person-group><article-title>Screening to identify unknown atrial fibrillation: a systematic review</article-title><source>Thromb Haemost.</source><year>2013</year><volume>110</volume><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1160/TH13-02-0165</pub-id><?supplied-pmid 23595785?><pub-id pub-id-type="pmid">23595785</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>January</surname><given-names>CT</given-names></name><name><surname>Wann</surname><given-names>LS</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Cigarroa</surname><given-names>JE</given-names></name><name><surname>Cleveland</surname><given-names>JC</given-names></name><etal/></person-group><article-title>2014 AHA/ACC/HRS guideline for the management of atrial fibrillation</article-title><source>Circulation</source><year>2014</year><volume>130</volume><fpage>e199</fpage><lpage>e267</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000041</pub-id><?supplied-pmid 24682347?><pub-id pub-id-type="pmid">24682347</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gage</surname><given-names>BF</given-names></name><name><surname>Waterman</surname><given-names>AD</given-names></name><name><surname>Shannon</surname><given-names>W</given-names></name><name><surname>Boechler</surname><given-names>M</given-names></name><name><surname>Rich</surname><given-names>MW</given-names></name><name><surname>Rathford</surname><given-names>MJ</given-names></name></person-group><article-title>Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation</article-title><source>Jama</source><year>2001</year><volume>285</volume><issue>22</issue><fpage>2864</fpage><lpage>2870</lpage><pub-id pub-id-type="doi">10.1001/jama.285.22.2864</pub-id><?supplied-pmid 11401607?><pub-id pub-id-type="pmid">11401607</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caro</surname><given-names>JJ</given-names></name></person-group><article-title>An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation</article-title><source>Thromb Res.</source><year>2015</year><volume>136</volume><issue>4</issue><fpage>727</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2015.07.007</pub-id><pub-id pub-id-type="pmid">26272305</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sindet-Peterson</surname><given-names>C</given-names></name><name><surname>Pallisgaard</surname><given-names>JL</given-names></name><name><surname>Olesen</surname><given-names>JB</given-names></name><name><surname>Gislason</surname><given-names>GH</given-names></name><name><surname>Arevalo</surname><given-names>LC</given-names></name></person-group><article-title>Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism-a systematic review and meta-analysis</article-title><source>Thromb Res.</source><year>2015</year><volume>136</volume><issue>4</issue><fpage>732</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2015.07.022</pub-id><pub-id pub-id-type="pmid">26277682</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>RG</given-names></name><name><surname>Pearce</surname><given-names>LA</given-names></name><name><surname>Aguilar</surname><given-names>MI</given-names></name></person-group><article-title>Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation</article-title><source>Ann Intern Med.</source><year>2007</year><volume>146</volume><issue>12</issue><fpage>857</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-146-12-200706190-00007</pub-id><?supplied-pmid 17577005?><pub-id pub-id-type="pmid">17577005</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>SJ</given-names></name><name><surname>Ezekowitz</surname><given-names>MB</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Eikelboom</surname><given-names>J</given-names></name><name><surname>Oldgren</surname><given-names>J</given-names></name><name><surname>Parekh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dabigatran versus warfarin in patients with atrial fibrillation</article-title><source>N Engl J Med.</source><year>2009</year><volume>361</volume><fpage>1139</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0905561</pub-id><?supplied-pmid 19717844?><pub-id pub-id-type="pmid">19717844</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Alexander</surname><given-names>JH</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Lopes</surname><given-names>RD</given-names></name><name><surname>Hylek</surname><given-names>EM</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><etal/></person-group><article-title>Apixaban versus warfarin in patients with atrial fibrillation</article-title><source>N Engl J Med.</source><year>2011</year><volume>365</volume><fpage>981</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1107039</pub-id><?supplied-pmid 21870978?><pub-id pub-id-type="pmid">21870978</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Mahaffery</surname><given-names>KW</given-names></name><name><surname>Garg</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>G</given-names></name><name><surname>Singer</surname><given-names>DE</given-names></name><name><surname>Hacke</surname><given-names>W</given-names></name><etal/></person-group><article-title>Rivaroxaban versus warfarin in nonvalvular atrial fibrillation</article-title><source>N Engl J Med.</source><year>2011</year><volume>365</volume><fpage>883</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1009638</pub-id><?supplied-pmid 21830957?><pub-id pub-id-type="pmid">21830957</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giugliano</surname><given-names>RP</given-names></name><name><surname>Ruff</surname><given-names>CT</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Murphy</surname><given-names>SA</given-names></name><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Edoxaban versus warfarin in patients with atrial fibrillation</article-title><source>N Engl J Med.</source><year>2013</year><volume>369</volume><issue>22</issue><fpage>2093</fpage><lpage>2104</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1310907</pub-id><?supplied-pmid 24251359?><pub-id pub-id-type="pmid">24251359</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oktay</surname><given-names>E</given-names></name></person-group><article-title>Will NOACs become the new standard of care in anticoagulation therapy?</article-title><source>Int J Cardiovasc Acad.</source><year>2015</year><volume>1</volume><issue>1</issue><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.ijcac.2015.06.007</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>GD</given-names></name><name><surname>Lucas</surname><given-names>E</given-names></name><name><surname>Alexander</surname><given-names>GC</given-names></name><name><surname>Goldberger</surname><given-names>ZD</given-names></name></person-group><article-title>National trends in ambulatory oral anticoagulant use</article-title><source>Am J Med.</source><year>2015</year><volume>128</volume><issue>12</issue><fpage>1300</fpage><lpage>1305.e2</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2015.05.044</pub-id><?supplied-pmid 26144101?><pub-id pub-id-type="pmid">26144101</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMinno</surname><given-names>A</given-names></name><name><surname>Spadarella</surname><given-names>G</given-names></name><name><surname>Tufano</surname><given-names>A</given-names></name><name><surname>Prisco</surname><given-names>D</given-names></name><name><surname>Di Minno</surname><given-names>G</given-names></name></person-group><article-title>Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs)</article-title><source>Thromb Res.</source><year>2014</year><volume>133</volume><issue>5</issue><fpage>699</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2014.01.016</pub-id><pub-id pub-id-type="pmid">24525314</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewen</surname><given-names>S</given-names></name><name><surname>Rettig-Ewen</surname><given-names>V</given-names></name><name><surname>Mahfoud</surname><given-names>F</given-names></name><name><surname>Bohm</surname><given-names>M</given-names></name><name><surname>Laufs</surname><given-names>U</given-names></name></person-group><article-title>Drug adherence in patients taking oral anticoagulation therapy</article-title><source>Clin Res Cardiol.</source><year>2014</year><volume>103</volume><issue>3</issue><fpage>173</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1007/s00392-013-0616-8</pub-id><?supplied-pmid 23999974?><pub-id pub-id-type="pmid">23999974</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gladstone</surname><given-names>DJ</given-names></name><name><surname>Geerts</surname><given-names>WH</given-names></name><name><surname>Douketis</surname><given-names>J</given-names></name><name><surname>Ivers</surname><given-names>N</given-names></name><name><surname>Healey</surname><given-names>JS</given-names></name><name><surname>Leblanc</surname><given-names>K</given-names></name></person-group><article-title>Anticoagulant monitoring checklist and quick-reference tables for managing patients on direct oral anticoagulants (DOACs) for stroke prevention in atrial fibrillation</article-title><source>Thromb Can.</source><year>2015</year><volume>163</volume><issue>5</issue><fpage>382</fpage><lpage>385</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shore</surname><given-names>S</given-names></name><name><surname>Carey</surname><given-names>EP</given-names></name><name><surname>Turakhia</surname><given-names>MP</given-names></name><name><surname>Jackevicius</surname><given-names>CA</given-names></name><name><surname>Cunningham</surname><given-names>F</given-names></name><name><surname>Pilote</surname><given-names>L</given-names></name><etal/></person-group><article-title>Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration</article-title><source>Am Heart J.</source><year>2014</year><volume>167</volume><issue>6</issue><fpage>810</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2014.03.023</pub-id><?supplied-pmid 24890529?><pub-id pub-id-type="pmid">24890529</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Kogut</surname><given-names>SJ</given-names></name><name><surname>Thompson</surname><given-names>S</given-names></name></person-group><article-title>Evaluation of differences in percentage of international normalized ratios in range between pharmacist-led and physician-led anticoagulation management services</article-title><source>J Pharm Pract.</source><year>2015</year><volume>28</volume><issue>3</issue><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1177/0897190013516368</pub-id><?supplied-pmid 24381239?><pub-id pub-id-type="pmid">24381239</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>S</given-names></name><name><surname>Barber</surname><given-names>A</given-names></name><name><surname>Sahm</surname><given-names>LJ</given-names></name></person-group><article-title>Pharmacist&#x02019;s counselling improves patient knowledge regarding warfarin, irrespective of health literacy level</article-title><source>Pharmacy</source><year>2014</year><volume>2</volume><issue>1</issue><fpage>114</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.3390/pharmacy2010114</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudd</surname><given-names>KM</given-names></name><name><surname>Dier</surname><given-names>JG</given-names></name></person-group><article-title>Comparison of two different models of anticoagulation management services with usual medical care</article-title><source>Pharmacotherapy</source><year>2010</year><volume>30</volume><issue>4</issue><fpage>330</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1592/phco.30.4.330</pub-id><?supplied-pmid 20334453?><pub-id pub-id-type="pmid">20334453</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castelluci</surname><given-names>LA</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><name><surname>van der Salm</surname><given-names>K</given-names></name><name><surname>Erkens</surname><given-names>P</given-names></name><name><surname>Le Gal</surname><given-names>G</given-names></name><name><surname>Petrcich</surname><given-names>W</given-names></name><etal/></person-group><article-title>Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale</article-title><source>Thromb Res.</source><year>2015</year><volume>136</volume><issue>4</issue><fpage>727</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2015.07.007</pub-id><pub-id pub-id-type="pmid">26272305</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>KB</given-names></name><name><surname>Formea</surname><given-names>CM</given-names></name><name><surname>Berg</surname><given-names>KD</given-names></name><name><surname>Burzynski</surname><given-names>JA</given-names></name><name><surname>Cunnigham</surname><given-names>JL</given-names></name><name><surname>Ou</surname><given-names>NN</given-names></name><etal/></person-group><article-title>Assessment of the pharmacogenomics educational needs of pharmacists</article-title><source>Am J Pharm Educ.</source><year>2011</year><volume>75</volume><issue>3</issue><fpage>51</fpage><pub-id pub-id-type="doi">10.5688/ajpe75351</pub-id><?supplied-pmid 21655405?><pub-id pub-id-type="pmid">21655405</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmens-Gruber</surname><given-names>R</given-names></name><name><surname>Hahnenkamp</surname><given-names>C</given-names></name><name><surname>Gossmann</surname><given-names>U</given-names></name><name><surname>Harreiter</surname><given-names>J</given-names></name><name><surname>Kamyar</surname><given-names>MR</given-names></name><name><surname>Johnson</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Evaluation of educational needs in patients with diabetes mellitus in respect of medication use in Austria</article-title><source>Int J Clin Pharm.</source><year>2012</year><volume>34</volume><issue>3</issue><fpage>490</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1007/s11096-012-9636-0</pub-id><?supplied-pmid 22527481?><pub-id pub-id-type="pmid">22527481</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budnitz</surname><given-names>DS</given-names></name><name><surname>Lovegrove</surname><given-names>MC</given-names></name><name><surname>Shehab</surname><given-names>N</given-names></name><name><surname>Richards</surname><given-names>CL</given-names></name></person-group><article-title>Emergency hospitalizations for adverse drug events in older Americans</article-title><source>N Engl J Med.</source><year>2011</year><volume>365</volume><issue>21</issue><fpage>2002</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1056/NEJMsa1103053</pub-id><?supplied-pmid 22111719?><pub-id pub-id-type="pmid">22111719</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elewa</surname><given-names>H</given-names></name><name><surname>Alhaddad</surname><given-names>A</given-names></name><name><surname>Al-Rawi</surname><given-names>S</given-names></name><name><surname>Nounou</surname><given-names>A</given-names></name><name><surname>Mahmoud</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name></person-group><article-title>Trends in oral anticoagulant use in Qatar: a 5-year experience</article-title><source>J Thromb Thrombolysis</source><year>2017</year><volume>43</volume><issue>3</issue><fpage>411</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1007/s11239-017-1474-4</pub-id><?supplied-pmid 28138812?><pub-id pub-id-type="pmid">28138812</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Akl</surname><given-names>EA</given-names></name><name><surname>Crowther</surname><given-names>M</given-names></name><name><surname>Gutterman</surname><given-names>DD</given-names></name><name><surname>Schuunemann</surname><given-names>HJ</given-names></name></person-group><article-title>Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines</article-title><source>Chest</source><year>2012</year><volume>2</volume><issue>Suppl</issue><fpage>7S</fpage><lpage>47S</lpage><pub-id pub-id-type="doi">10.1378/chest.1412S3</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>CTT</given-names></name></person-group><source>Continuing Professional Development/Continuing Education in Pharmacy: Global Report</source><year>2014</year><publisher-loc>The Hague</publisher-loc><publisher-name>International Pharmaceutical Federation</publisher-name></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prot-Labarthe</surname><given-names>S</given-names></name><name><surname>Stil-Baudry</surname><given-names>J</given-names></name><name><surname>Fahd</surname><given-names>M</given-names></name><name><surname>Brion</surname><given-names>F</given-names></name><name><surname>Bourdon</surname><given-names>O</given-names></name></person-group><article-title>The role of community pharmacists in the management of hematopoietic stem cell transplant recipients: knowledge and training</article-title><source>J Pediatr Hematol Oncol.</source><year>2013</year><volume>35</volume><issue>3</issue><fpage>188</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1097/MPH.0b013e3182707aff</pub-id><?supplied-pmid 23042014?><pub-id pub-id-type="pmid">23042014</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bascom</surname><given-names>CS</given-names></name><name><surname>Rosenthal</surname><given-names>MM</given-names></name><name><surname>Houle</surname><given-names>SK</given-names></name></person-group><article-title>Are pharmacists ready for a greater role in travel health? An evaluation of the knowledge and confidence in providing travel health advice of pharmacists practicing in a community pharmacy chain in Alberta, Canada</article-title><source>J Travel Med.</source><year>2015</year><volume>22</volume><issue>2</issue><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1111/jtm.12172</pub-id><?supplied-pmid 25410438?><pub-id pub-id-type="pmid">25410438</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taing</surname><given-names>MW</given-names></name><name><surname>Tan</surname><given-names>ET</given-names></name><name><surname>Williams</surname><given-names>GM</given-names></name><name><surname>Clavarino</surname><given-names>AM</given-names></name><name><surname>McGuire</surname><given-names>TM</given-names></name></person-group><article-title>Herbal and nutrient complementary medicines for weight loss: community pharmacists&#x02019; practices, attitudes, recommendations, information and education needs</article-title><source>Int J Pharm Pract.</source><year>2016</year><volume>24</volume><issue>3</issue><fpage>160</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1111/ijpp.12232</pub-id><?supplied-pmid 26671003?><pub-id pub-id-type="pmid">26671003</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Saleh</surname><given-names>H</given-names></name><name><surname>Al-Houtan</surname><given-names>T</given-names></name><name><surname>Al-Odaill</surname><given-names>K</given-names></name><name><surname>Al-Mutairi</surname><given-names>B</given-names></name><name><surname>Al-Muaybid</surname><given-names>M</given-names></name><name><surname>Al-Falah</surname><given-names>T</given-names></name><etal/></person-group><article-title>Role of community pharmacists in providing oral health advice in the Eastern province of Saudi Arabia</article-title><source>Saudi Dent J.</source><year>2017</year><volume>29</volume><issue>3</issue><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.sdentj.2017.03.004</pub-id><?supplied-pmid 28725130?><pub-id pub-id-type="pmid">28725130</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kheir</surname><given-names>N</given-names></name><name><surname>Zaidan</surname><given-names>M</given-names></name><name><surname>Younes</surname><given-names>H</given-names></name><name><surname>El Hajj</surname><given-names>M</given-names></name><name><surname>Wilbur</surname><given-names>K</given-names></name><name><surname>Jewesson</surname><given-names>PJ</given-names></name></person-group><article-title>Pharmacy education and practice in 13 Middle Eastern countries</article-title><source>Am J Pharm Educ.</source><year>2008</year><volume>72</volume><issue>6</issue><fpage>133</fpage><pub-id pub-id-type="doi">10.5688/aj7206133</pub-id><?supplied-pmid 19325953?><pub-id pub-id-type="pmid">19325953</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caldeira</surname><given-names>A</given-names></name><name><surname>Papastergiou</surname><given-names>J</given-names></name><name><surname>Kheir</surname><given-names>N</given-names></name><name><surname>Rydant</surname><given-names>S</given-names></name><name><surname>Antoniou</surname><given-names>S</given-names></name><name><surname>Costa</surname><given-names>FA</given-names></name></person-group><article-title>Portuguese pharmacists&#x02019; perceived needs of education in anticoagulation</article-title><source>Int J Clin Pharm.</source><year>2017</year></element-citation></ref></ref-list></back></article>